Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science
The Journal of Clinical Pharmacology · 2026-07 · 66 (7)
DOI: 10.1002/jcph.70242 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 24.07.2026. Verfasst von Ya-Feng Wen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Sciences, Gilead Sciences, Inc., Foster City, CA, USA. Hauptthemen laut MEDLINE: Drug Development, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for pediatric populations, driven by advances in molecularly targeted treatments, evolving regulatory requirements, and innovation in trial design. Reducing nonclinical data requirements and increasing the adaptation of model‑informed drug development approaches are also contributing to advances in pediatric oncology treatment by supporting dose selection, optimizing study design, and reducing unnecessary patient burden. In this review, recent regulatory requirements from the United States, the EU, and other key regions on pediatric oncology drug development are discussed. Thirty‐three drugs with oncology indications in pediatric populations approved by the US FDA between 2018 and 2025 are reviewed. These approvals provide examples of how nonclinical and clinical data were generated with a focus on strategies for dose‐finding and justification. Common challenges and considerations related to clinical operations and formulation development in pediatric populations and the emerging use of real‐world data, external controls, and artificial intelligence/machine learning are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
- Regulatory Affairs, Gilead Sciences, Inc., Foster City, CA, USA.
- Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.
- Biostatistics, Gilead Sciences, Inc., Foster City, CA, USA.
Zitieren
APA
Wen, Y. F., Wang, X., Boyanapalli, S., Anderson, L., Dang, T., Xing, G., Calvet, M., Hart, T., Kasichayanula, S., & Zhao, X. (2026). Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science. The Journal of Clinical Pharmacology, 66(7). https://doi.org/10.1002/jcph.70242
Vancouver
Wen YF, Wang X, Boyanapalli S, Anderson L, Dang T, Xing G, et al. Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science. The Journal of Clinical Pharmacology. 2026;66(7). doi:10.1002/jcph.70242
BibTeX
@article{Wen2026,
author = {Wen, Ya-Feng and Wang, Xiaoning and Boyanapalli, Sarandeep and Anderson, Lee and Dang, Thao and Xing, Guan and Calvet, Marianna and Hart, Tiffany and Kasichayanula, Sreeneeranj and Zhao, Xiaochen},
title = {Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {7},
doi = {10.1002/jcph.70242}
}
EUVIMED